Monoclonal antibody · Antagonist of hemojuvelin (HJV) · developed by Disc Medicine
Selcodebart (DISC-0974) is a humanized monoclonal antibody that binds hemojuvelin, a BMP co-receptor, blocking its signaling and thereby suppressing hepcidin synthesis to increase iron availability. It is studied in anemia and inflammatory bowel disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07368972 | Phase 2 | Inflammatory Bowel Disease (IBD) | Recruiting | IRON |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AnemiaInflammatory Bowel Disease (IBD)Inflammatory Bowel Disease (IBD); Anemia
Updated Nov 15, 2026. Something wrong or missing? Report it on the IRON page.
See IRON's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IRON catalysts and pipeline →